{"id":"W4402560337","doi":"10.1016/j.annonc.2024.08.1489","title":"1423P Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Ipsen; Cilag; Astellas Pharma; Eisai; National Institute for Health and Care Research; Servier; Moderna; Incyte; EUSA Pharma; Seagen; Gilead Sciences; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Gastro-; Chemotherapy; Internal medicine; Adenocarcinoma; Metastatic adenocarcinoma; Oncology; Esophageal adenocarcinoma; Cancer; Disease; Reflux","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008287671,0.0007721794,0.001781866,0.0003372322,0.000248021,0.001013951,0.0005101587,0.0007056877,0.007172011],"category_scores_gemma":[0.0007355963,0.0003274922,0.001439251,0.0003969917,0.0004673327,0.0006568509,0.0003285542,0.002327771,0.001354351],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006857413,"about_ca_system_score_gemma":0.000834508,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001401568,"about_ca_topic_score_gemma":0.007721303,"domain_scores_codex":[0.9997641,0.00008919636,0.00001650927,0.000042402,0.00003278198,0.0000549174],"domain_scores_gemma":[0.999764,0.00004608913,0.00006959118,0.00001997275,0.00002085783,0.00007944971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4865022,0.0102474,0.008886548,0.00747202,0.008216549,0.0002802038,0.0002653805,0.003688829,0.02434834,0.001265656,0.02563362,0.4231932],"study_design_scores_gemma":[0.8341078,0.1074123,0.02434247,0.0004863006,0.004048808,0.0005555798,0.0001163385,0.001586853,0.002719946,0.0008896542,0.02366516,0.00006882336],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9404963,0.03302357,0.001059936,0.002610054,0.001186768,0.002562451,0.006251188,0.0003570551,0.01245281],"genre_scores_gemma":[0.9440417,0.02601576,0.002750243,0.00357811,0.0003497509,0.001682575,0.009183994,0.0001002695,0.01229753],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007172011,"threshold_uncertainty_score":0.02399278,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1966977244664351,"score_gpt":0.4561171381704844,"score_spread":0.2594194137040493,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}